
<DOC>
<DOCNO>WT01-B04-8</DOCNO>
<DOCOLDNO>IA046-000815-B034-20</DOCOLDNO>
<DOCHDR>
http://www.gothic.net:80/product/2_3_2.htm 205.178.27.23 19970119003136 text/html 13646
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sun, 19 Jan 1997 00:34:50 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Thu, 17 Oct 1996 22:24:40 GMT
Content-Length: 13447
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Supergenerics</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<P><MAP NAME="newnav"><AREA SHAPE=rect COORDS="396,1,440,12" HREF="../people/5_0.htm"><AREA SHAPE=poly COORDS="344,11,374,2,391,16,394,30,371,37,368,61,349,59,341,33,344,11" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="435,54,495,65" HREF="../product/2_0.htm"><AREA SHAPE=poly COORDS="406,27,424,46,428,72,407,94,386,90,385,84,369,66,369,61,371,38,406,27" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="393,114,525,124" HREF="../patent/4_0.htm"><AREA SHAPE=poly COORDS="330,75,366,64,384,86,390,110,366,134,334,126,325,103,330,75" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="205,75,271,96" HREF="../invest/6_0.htm"><AREA SHAPE=poly COORDS="313,56,329,74,324,102,327,110,313,123,286,117,273,91,279,65,313,56" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="196,30,282,41" HREF="../perform/3_0.htm"><AREA SHAPE=poly COORDS="291,28,323,16,338,34,345,58,330,72,313,54,290,61,286,49,291,28" HREF="../perform/3_0.htm"><AREA SHAPE=rect COORDS="8,2,105,25" HREF="../index.htm"><AREA SHAPE=rect COORDS="9,46,81,61" HREF="../contact.htm"><AREA SHAPE=rect COORDS="10,62,80,77" HREF="../search.htm"><AREA SHAPE=rect COORDS="10,78,79,93" HREF="../map.htm"></MAP>
</P>

<P><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0 WIDTH=557 HEIGHT=35>
   <TR>
      <TD>
         <P><IMG SRC="../images/newnav.gif" WIDTH=528 HEIGHT=136
         BORDER=0 ALIGN=bottom usemap="#newnav">
      </TD></TR>
   <TR>
      <TD>
         <P><MAP NAME="2"><AREA SHAPE=rect COORDS="140,51,232,67" HREF="2_0.htm"><AREA SHAPE=rect COORDS="30,85,88,96" HREF="2_3.htm"></MAP>
         </P>
         
         <P><IMG SRC="images/2_3_2.gif" WIDTH=241 HEIGHT=117 BORDER=0
         ALIGN=bottom usemap="#2">
      </TD></TR>
</TABLE></P>

<P><TABLE BORDER=0 CELLPADDING=1 WIDTH=590>
   <TR>
      <TD COLSPAN=8>
         <BLOCKQUOTE><P><FONT SIZE=4>The Company is developing
         "supergenerics" that it believes may significantly improve
         the safety profile and handling characteristics of certain
         generic anticancer drugs currently on the market (the
         "supergeneric technology"). Some anticancer generic drugs
         are available only in a powder form and have to be mixed and
         dissolved in the correct liquid prior to administration. The
         Company's supergeneric technology enables certain anticancer
         drugs to be made in ready-to-inject, stable solutions. The
         ready-to-inject stable solution not only increases the ease
         of administration and saves time by eliminating the mixing
         procedure, but also increases the safety for the person
         administering the dose by minimizing the risk of exposure to
         these toxic drugs. Moreover, the Company believes that
         certain of its ready-to-inject, stable solutions may have a
         significantly longer shelf-life at room-temperature than the
         mixed generic solutions. </FONT></P>
         
         <P><FONT SIZE=4>In addition, the Company believes that its
         supergeneric technology may increase the safety of certain
         existing anticancer drugs by minimizing the problem of
         ulceration associated with extravasation. Extravasation is
         accidental leakage of the drug into a patient's muscle or
         skin from a blood vessel. Many existing anticancer
         pharmaceuticals, including those under development by the
         Company, can cause serious ulceration if extravasated. The
         resulting damage can be extensive and can require plastic
         surgery to repair. As a result, the Company believes that
         its supergeneric products may have a significant competitive
         advantage over their generic counterparts currently on the
         market. </FONT></P>
         
         <P><FONT SIZE=4>The Company has filed an application for
         worldwide patent protection for certain of its anticancer
         supergeneric products. The U.S. patent for these
         applications has been allowed. </FONT></P>
         
         <P><FONT SIZE=4>The Company's supergeneric drugs currently
         under development are as follows:<A NAME="1"></A> </FONT>
         </P>
         
         <P>&nbsp;</BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD VALIGN=bottom COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">M</FONT></B><FONT SIZE=5 COLOR="#232B68">itoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP><FONT SIZE=5 COLOR="#232B68">
         </FONT>
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD VALIGN=top COLSPAN=2>
         <P>
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=85 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=8>
         <BLOCKQUOTE><P><FONT SIZE=4>Mitomycin is currently available
         commercially in powder form only. The Company has completed
         its formulation and preclinical testing for its Mitomycin
         Extra<sup>tm</sup> for injection and has filed an IND with the FDA and
         begun Phase I/II trials<A NAME="2"></A></FONT></P>
         
         <P>&nbsp;</BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD COLSPAN=8>
         <P>
      </TD></TR>
   <TR>
      <TD VALIGN=bottom COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">P</FONT></B><FONT SIZE=5 COLOR="#232B68">acoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP><FONT SIZE=5 COLOR="#232B68">
         </FONT>
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD VALIGN=top COLSPAN=2>
         <P>
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=8>
         <BLOCKQUOTE><P><FONT SIZE=4>Paclitaxel is indicated as
         second-line therapy to treat ovarian cancer. It is the
         fastest growing anticancer agent, with sales in the U.S. of
         approximately </FONT><B><FONT SIZE=4>$386.5 million in 1995
         and $262.2 million in 1994.</FONT></B><FONT SIZE=4> The
         current paclitaxel formulation has numerous problems because
         the high level of Cremophor&reg;EL solvent used for the
         injection concentrate causes hypersensitivity reactions,
         leaching of plasticizer from PVC infusion bags, haziness of
         diluted solutions and the need for in-line filters. The
         Company believes that its potential product may eliminate or
         minimize these problems.<A NAME="3"></A></FONT></P>
         
         <P>&nbsp;</BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD VALIGN=bottom COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">D</FONT></B><FONT SIZE=5 COLOR="#232B68">oxoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP>
      
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD VALIGN=top COLSPAN=2>
         <P>
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=8>
         <BLOCKQUOTE><P><FONT SIZE=4>Doxorubicin is indicated to
         treat major cancers including acute lymphoblastic and
         myeloblastic leukemia, malignant lymphoma, breast and
         ovarian carcinoma, soft tissue and bone sarcomas,
         neuroblastoma osteosarcoma, Wilms' tumor and others.
         Doxorubicin is currently sold as a powder by four companies,
         and in solution form by two of these companies. Sales of
         Doxorubicin in the U.S. were estimated to be approximately
         </FONT><B><FONT SIZE=4>$55.3 million in 1995 and $60.9
         million in 1994</FONT></B><FONT SIZE=4>, of which sales of
         the solution form represented 75.8% and 76.7%,
         respectively.<A NAME="4"></A> </FONT></P>
         
         <P>&nbsp;</BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD VALIGN=bottom COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">D</FONT></B><FONT SIZE=5 COLOR="#232B68">aunoExtra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP>
      
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD VALIGN=top COLSPAN=2>
         <P>
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=8>
         <BLOCKQUOTE><P><FONT SIZE=4>Daunorubicin is indicated to
         treat acute nonlymphocytic and acute lymphocytic leukemia.
         Sales of daunorubicin in the U.S. were estimated to be
         approximately </FONT><B><FONT SIZE=4>$10.9 million in 1995
         and $10.3 million in 1994.</FONT></B><FONT SIZE=4>
         Daunorubicin is currently sold in powder form only. The
         Company believes that daunorubicin represents a niche market
         with limited competition from large pharmaceutical companies
         due to its relatively small market size. However, the
         Company believes the use of daunorubicin may increase
         substantially in the future, as recent experimental studies
         suggest that daunorubicin may be used in an increasing
         number of combination drug protocols treating a number of
         cancers.<A NAME="5"></A></FONT></P>
         
         <P>&nbsp;</BLOCKQUOTE>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD VALIGN=bottom COLSPAN=2>
         <P><B><FONT SIZE=5 COLOR="#232B68">C</FONT></B><FONT SIZE=5 COLOR="#232B68">isplatin</FONT>
      
      </TD><TD COLSPAN=6>
         <P><IMG SRC="images/markers.gif" WIDTH=425 HEIGHT=23
         ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD VALIGN=top COLSPAN=2>
         <P><FONT SIZE=5 COLOR="#232B68">Extra</FONT><SUP><FONT SIZE=5 COLOR="#232B68">tm</FONT></SUP>
      
      </TD><TD VALIGN=top COLSPAN=6>
         <P><IMG SRC="images/barL.gif" WIDTH=7 HEIGHT=15 BORDER=0
         ALIGN=bottom><IMG SRC="images/barC.gif" WIDTH=45 HEIGHT=15
         BORDER=0 ALIGN=bottom><IMG SRC="images/barR.gif" WIDTH=8
         HEIGHT=15 BORDER=0 ALIGN=bottom>
      </TD></TR>
   <TR>
      <TD COLSPAN=8>
         <P>
      </TD></TR>
   <TR>
      <TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD><TD>
         <P>
      </TD></TR>
   <TR>
      <TD COLSPAN=8>
         <BLOCKQUOTE><P><FONT SIZE=4>Cisplatin is indicated for the
         treatment of metastatic testicular tumors, metastatic
         ovarian tumors and advanced bladder cancer. Sales of
         cisplatin in the U.S. were estimated to be approximately
         </FONT><B><FONT SIZE=4>$41.4 million in 1995 and $42.4
         million in 1994</FONT></B><FONT SIZE=4>.</FONT></P>
         
         <P><FONT SIZE=4>&nbsp;</FONT></P>
         
         <P><FONT SIZE=4>&nbsp;</FONT></P>
         
         <P><FONT SIZE=4>The Company currently intends to develop
         other supergeneric products, such as VP-16 Extra, to
         complement its anticancer product portfolio. The Company
         continues to research other applications to use its
         supergeneric technology to enhance existing anticancer
         drugs. </FONT></BLOCKQUOTE>
      </TD></TR>
</TABLE></P>

<P>&nbsp;</P>

<P><MAP NAME="lowNAV"><AREA SHAPE=rect COORDS="67,10,111,19" HREF="../people/5_0.htm"><AREA SHAPE=rect COORDS="128,11,186,19" HREF="../product/2_0.htm"><AREA SHAPE=rect COORDS="204,11,336,19" HREF="../patent/4_0.htm"><AREA SHAPE=rect COORDS="353,11,403,19" HREF="../invest/6_0.htm"><AREA SHAPE=rect COORDS="420,11,504,19" HREF="../perform/3_0.htm"></MAP><IMG
SRC="../images/lowNAV.gif" WIDTH=530 HEIGHT=31 BORDER=0 ALIGN=bottom
usemap="#lowNAV"></P>
</BODY>
</HTML>
</DOC>